329
Participants
Start Date
January 31, 2015
Primary Completion Date
June 7, 2018
Study Completion Date
June 7, 2018
Intravenous hyperimmune immunoglobulin (IVIG)
Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)
Placebo for IVIG
Administered IV as 500 mL of normal saline
Cornell CRS, New York
Montefiore Medical Center, The Bronx
University of Pittsburgh, Pittsburgh
National Institutes of Health Clinical Center, Bethesda
West Virginia University, Morgantown
Duke University, Durham
OHIO State University (OSU) Wexner Medical Center, Columbus
Case Western Reserve University, Cleveland
Miami Valley Hospital, Dayton
Henry Ford Hospital, Detroit
Minneapolis VA Medical Center, Minneapolis
Mayo Clinic, Rochester
University of Illinois, Chicago
UT Southwestern Medical Center, Dallas
Denver Public Health, Denver
UCSD Antiviral Research Center (A VRC), San Diego
Cooper University Hospital, Camden
Westmead Hospital, Sydney
Odense University Hospital, Odense
St James's University Hospital, Leeds
Churchill Hospital, Oxford
University of Minnesota
OTHER
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
NETWORK
National Institute of Allergy and Infectious Diseases (NIAID)
NIH